NASDAQ Stock Exchange News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 976,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "32b6eeab-83e7-40a0-a8e5-be4c886bd7da",
"title": "Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023",
"description": "GAAP Costs and Expenses: Rose to $12.5 million in Q4 2023 from $8.7 million in Q4 2022.Net Loss: GAAP net loss narrowed to ($42.2) million in 2023 from ($58.5)",
"keywords": "GuruFocus, Article, News, GuruFocus Research, PLSE",
"snippet": "On March 28, 2024, Pulse Biosciences Inc (PLSE, Financial) released its 8-K filing, detailing the financial results for the fourth quarter and full year ended D...",
"url": "https://www.gurufocus.com/news/2399543/pulse-biosciences-inc-plse-reports-increased-gaap-costs-and-narrowed-net-loss-in-2023",
"image_url": "https://static.gurufocus.com/logos/0C0000B1P2.png?5",
"language": "en",
"published_at": "2024-03-28T21:51:44.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "PLSE",
"name": "Pulse Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 120.8934,
"sentiment_score": 0.311643,
"highlights": [
{
"highlight": "On March 28, 2024, <em>Pulse</em> <em>Biosciences</em> <em>Inc</em> (PLSE, Financial) released its 8-K filing, detailing the financial results for the fourth quarter and full year ended December 31, 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pulse</em> <em>Biosciences</em> <em>Inc</em> (PLSE, Financial) reported that its GAAP costs and expenses for Q4 2023 were $12.5 million, up from $8.7 million in the prior year period.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pulse</em> <em>Biosciences</em> <em>Inc</em> (PLSE, Financial) is well-positioned to continue its product development initiatives, with the potential to bring innovative treatments to market.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Investors interested in the detailed financials can join <em>Pulse</em> <em>Biosciences</em>’ management for a conference call on March 28, 2024, at 1:30 pm PT or access the webcast at <em>Pulse</em> <em>Biosciences</em> Investor Relations.",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "For a more comprehensive understanding of <em>Pulse</em> <em>Biosciences</em> <em>Inc</em> (PLSE, Financial)'s financial performance, including reconciliations of GAAP to non-GAAP financial measures, readers are encouraged to review the full financial statements and accompanying notes.",
"sentiment": 0.5809,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pulse</em> <em>Biosciences</em> remains committed to leveraging its CellFX nsPFA technology to improve patient outcomes, and its financial results reflect both the investment in this mission and the company's prudent management of its resources.\n\nExplore the complete 8-K earnings release (here) from <em>Pulse</em> <em>Biosciences</em> <em>Inc</em> for further details.",
"sentiment": 0.6124,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Pulse</em> <em>Biosciences</em> <em>Inc</em> (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023",
"sentiment": -0.0516,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "0fe4072b-9828-482e-a642-e5e0715051ed",
"title": "Forian Inc (FORA) Outperforms Analyst Revenue Estimates and Achieves Positive Adjusted EBITDA",
"description": "Revenue: Q4 revenue of $5.368 million, surpassing analyst estimates of $5.4515 million.Net Income: Q4 net income of $1.388 million, a significant turnaround fr",
"keywords": "GuruFocus, Article, News, GuruFocus Research, FORA",
"snippet": "On March 28, 2024, Forian Inc (FORA, Financial), a provider of data science driven information and analytics solutions to the healthcare and life sciences indus...",
"url": "https://www.gurufocus.com/news/2399542/forian-inc-fora-outperforms-analyst-revenue-estimates-and-achieves-positive-adjusted-ebitda",
"image_url": "https://static.gurufocus.com/logos/0C0000BZCR.png?5",
"language": "en",
"published_at": "2024-03-28T21:51:43.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "FORA",
"name": "Forian Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 121.97922,
"sentiment_score": 0.38516,
"highlights": [
{
"highlight": "On March 28, 2024, <em>Forian</em> <em>Inc</em> (<em>FORA</em>, Financial), a provider of data science driven information and analytics solutions to the healthcare and life sciences industries, announced its financial results for the fourth quarter and full year ended December 31, 2023.",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Forian</em> <em>Inc</em> (<em>FORA</em>) released its 8-K filing showcasing a year of substantial financial progress, with full-year revenue growth of 25% and a positive Adjusted EBITDA of $2.3 million.",
"sentiment": 0.8689,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Forian</em> <em>Inc</em> provides a suite of SaaS solutions, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the healthcare and life sciences sectors, as well as cannabis dispensaries, manufacturers, cultivators, and regulators.",
"sentiment": 0.7184,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Forian</em> <em>Inc</em> (<em>FORA</em>, Financial)'s performance in the fourth quarter demonstrated a significant improvement, with revenue increasing by 8% to $5.368 million, exceeding the estimated $5.4515 million.",
"sentiment": 0.5859,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Forian</em> <em>Inc</em> (<em>FORA</em>, Financial)'s focus on the healthcare and life sciences sectors positions it well to capitalize on the growing demand for data analytics and precision medicine.",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "Key financial details from the year-end report include:\n\nFinancial Metrics Q4 2023 Full Year 2023 Revenue $5.368 million $20.481 million Net Income $1.388 million $11.106 million Adjusted EBITDA $1.033 million $2.336 million EPS (Diluted) $0.04 $0.34 Cash and Equivalents $6.043 million -\n\nMax Wygod, Chairman and CEO of <em>Forian</em>, commented on the results",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": ", stating,\n\n<em>Forian</em> finished the year by executing against our quarterly plan and closed what was a transformational year.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Forian</em> <em>Inc</em> (<em>FORA</em>, Financial) also provided an outlook for the full year 2024, indicating a continued focus on growth and operational efficiency.",
"sentiment": 0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Forian</em> <em>Inc</em> (<em>FORA</em>, Financial) will discuss these results in a conference call and webcast later today.\n\nExplore the complete 8-K earnings release (here) from <em>Forian</em> <em>Inc</em> for further details.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Forian</em> <em>Inc</em> (<em>FORA</em>) Outperforms Analyst Revenue Estimates and Achieves Positive Adjusted EBITDA",
"sentiment": 0.5574,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "2cde402e-0e9e-4317-9d77-54e99012eb7e",
"title": "Handel in New York: NASDAQ Composite verbucht letztendlich Abschläge",
"description": "So bewegte sich der NASDAQ Composite am vierten Tag der Woche schlussendlich. 28.03.2024",
"keywords": "",
"snippet": "NASDAQ Composite-Performance\n\nSo bewegte sich der NASDAQ Composite am vierten Tag der Woche schlussendlich.\n\nLetztendlich schloss der NASDAQ Composite nahezu un...",
"url": "https://www.finanzen.net/nachricht/aktien/handel-in-new-york-nasdaq-composite-verbucht-letztendlich-abschlaege-13380973",
"image_url": "https://images.finanzen.net/mediacenter/unsortiert/nasdaq-composite-lufeta-shutterstock-2319520601-660.jpg",
"language": "de",
"published_at": "2024-03-28T21:32:30.000000Z",
"source": "finanzen.net",
"relevance_score": null,
"entities": [
{
"symbol": "TAYD",
"name": "Taylor Devices, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 36.984848,
"sentiment_score": null,
"highlights": [
{
"highlight": "Tops und Flops im NASDAQ Composite aktuell\n\nZu den Top-Aktien im NASDAQ Composite zählen aktuell Escalon Medical (+ 18,10 Prozent auf 0,25 USD), inTest (+ 16,53 Prozent auf 13,25 USD), <em>Taylor</em> <em>Devices</em> (+ 13,68 Prozent auf 49,77 USD), Cumulus Media A (+ 11,15 Prozent auf 3,59 USD) und Ebix (+ 7,41 Prozent auf 1,00 USD).",
"sentiment": 0.1027,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "b3ecbfed-8371-4592-bbd3-7035328f03f8",
"title": "Sharecare Inc (SHCR) Reports Earnings: A Mixed Bag Against Analyst Expectations",
"description": "Revenue: Q4 revenue fell to $105.3 million, down 15% year-over-year and missing analyst estimates of $117.582 million.Net Loss: Increased to $34.2 million in Q",
"keywords": "GuruFocus, Article, News, GuruFocus Research, SHCR",
"snippet": "On March 28, 2024, Sharecare Inc (SHCR, Financial) released its 8-K filing, disclosing its financial results for the fourth quarter and full year of 2023. The d...",
"url": "https://www.gurufocus.com/news/2399486/sharecare-inc-shcr-reports-earnings-a-mixed-bag-against-analyst-expectations",
"image_url": "https://static.gurufocus.com/logos/0C0000C6S3.png?5",
"language": "en",
"published_at": "2024-03-28T21:32:23.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "SHCR",
"name": "Sharecare, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 141.61746,
"sentiment_score": 0.303413,
"highlights": [
{
"highlight": "On March 28, 2024, <em>Sharecare</em> <em>Inc</em> (<em>SHCR</em>, Financial) released its 8-K filing, disclosing its financial results for the fourth quarter and full year of 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "For the fourth quarter, <em>Sharecare</em> reported revenue of $105.3 million, a decrease of 15% compared to the same period last year. This decline was partly due to the elimination of nonperforming disputed contracts, which negatively impacted revenue by $14.2 million.",
"sentiment": -0.34,
"highlighted_in": "main_text"
},
{
"highlight": "Brent Layton, CEO of <em>Sharecare</em>, expressed confidence in the company's innovation capabilities and the momentum in expanding their services to new markets, such as Medicaid and Medicare.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Sharecare</em> is currently undergoing a strategic review process, evaluating multiple proposals for a potential sale transaction and alternative value-creation opportunities. The special committee aims to maximize shareholder value, with a decision to be communicated upon conclusion of the review process.",
"sentiment": 0.7717,
"highlighted_in": "main_text"
},
{
"highlight": "As <em>Sharecare</em> continues to navigate its strategic review and potential restructuring, the company's ability to innovate and optimize costs will be crucial in driving future profitability and shareholder value.",
"sentiment": 0.9042,
"highlighted_in": "main_text"
},
{
"highlight": "Investors and stakeholders will be watching closely as <em>Sharecare</em> moves forward with its strategic initiatives and responds to the dynamic healthcare market.\n\nFor a more in-depth analysis and updates on <em>Sharecare</em> <em>Inc</em> (<em>SHCR</em>, Financial), stay tuned to GuruFocus.com.",
"sentiment": 0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Explore the complete 8-K earnings release (here) from <em>Sharecare</em> <em>Inc</em> for further details.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Sharecare</em> <em>Inc</em> (<em>SHCR</em>) Reports Earnings: A Mixed Bag Against Analyst Expectations",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "5459036d-2724-4cbd-baf4-41444f3eccf4",
"title": "Achieve Life Sciences Inc Reports Year-End Loss, Progresses Towards FDA Approval",
"description": "Net Loss: Reported a net loss of $29.8 million for the year ended December 31, 2023.EPS: Basic and diluted net loss per share of $1.50, aligning with analyst e",
"keywords": "GuruFocus, Article, News, GuruFocus Research, ACHV",
"snippet": "Achieve Life Sciences Inc (ACHV, Financial) released its 8-K filing on March 28, 2024, detailing its financial results for the fourth quarter and year-end 2023....",
"url": "https://www.gurufocus.com/news/2399485/achieve-life-sciences-inc-reports-yearend-loss-progresses-towards-fda-approval",
"image_url": "https://static.gurufocus.com/logos/0C0000094G.png?5",
"language": "en",
"published_at": "2024-03-28T21:32:07.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ACHV",
"name": "Achieve Life Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 162.0972,
"sentiment_score": 0.4235,
"highlights": [
{
"highlight": "<em>Achieve</em> <em>Life</em> <em>Sciences</em> <em>Inc</em> (ACHV, Financial) released its 8-K filing on March 28, 2024, detailing its financial results for the fourth quarter and year-end 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Achieve</em> <em>Life</em> <em>Sciences</em> is a specialty pharmaceutical company committed to advancing cytisinicline as a treatment option to help people battling nicotine addiction.",
"sentiment": 0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "Financial Performance and Corporate Highlights\n\nIn the recent earnings release, <em>Achieve</em> <em>Life</em> <em>Sciences</em> highlighted several corporate achievements and challenges. The company reached an agreement with the U.S. Food and Drug Administration (FDA) on long-term cytisinicline exposure requirements to support a New Drug Application (NDA) submission.",
"sentiment": 0.765,
"highlighted_in": "main_text"
},
{
"highlight": "The importance of these achievements cannot be overstated for a biotechnology company like <em>Achieve</em> <em>Life</em> <em>Sciences</em>. The agreement with the FDA represents a significant step towards commercialization, and the successful financing provides the necessary capital to continue the development of cytisinicline.",
"sentiment": 0.9153,
"highlighted_in": "main_text"
},
{
"highlight": "Year-End Financial Results and Future Outlook\n\n<em>Achieve</em> <em>Life</em> <em>Sciences</em> reported total operating expenses for the fourth quarter and year ended December 31, 2023, of $4.4 million and $27.3 million, respectively.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "For more detailed financial data and insights into <em>Achieve</em> <em>Life</em> <em>Sciences</em> Inc's performance, visit GuruFocus.com, where we provide in-depth analysis and up-to-date information for value investors and potential members.\n\nExplore the complete 8-K earnings release (here) from <em>Achieve</em> <em>Life</em> <em>Sciences</em> <em>Inc</em> for further details.",
"sentiment": 0.34,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Achieve</em> <em>Life</em> <em>Sciences</em> <em>Inc</em> Reports Year-End Loss, Progresses Towards FDA Approval",
"sentiment": 0.2023,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "621c9526-e9ff-425b-a67c-17bce4707db5",
"title": "Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update",
"description": "Company to host investor call and webcast on Monday, April 1st, at 8:30am EDT...",
"keywords": "Nasdaq:POAI, Predictive Oncology Inc.",
"snippet": "PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence a...",
"url": "https://www.globenewswire.com/news-release/2024/03/28/2854541/37244/en/Predictive-Oncology-Reports-Year-End-2023-Financial-Results-and-Provides-Business-Update.html",
"image_url": "https://ml.globenewswire.com/Resource/Download/0236a5ac-4b8b-49f2-b874-dc0240853807",
"language": "en",
"published_at": "2024-03-28T21:28:00.000000Z",
"source": "globenewswire.com",
"relevance_score": null,
"entities": [
{
"symbol": "POAI",
"name": "Predictive Oncology Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 81.26511,
"sentiment_score": 0.020938,
"highlights": [
{
"highlight": "PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) -- <em>Predictive</em> <em>Oncology</em> (<em>Nasdaq</em>: <em>POAI</em>), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "Per the terms of the collaboration, <em>Predictive</em> <em>Oncology</em> will play a critical role in helping to make FluGen’s M2SR flu vaccine more stable and sustainable as it advances through clinical trials.",
"sentiment": 0.2878,
"highlighted_in": "main_text"
},
{
"highlight": "Continued to engage with Cancer Research Horizons (CRH) on next steps following delivery of preliminary results from its first campaign with CRH, in which <em>Predictive</em> <em>Oncology</em> determined, with a high degree of accuracy, which cancer types and patient populations are most likely to respond to pre-clinical glutaminase inhibitors, informing future clinical",
"sentiment": -0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Predictive</em> <em>Oncology</em> sees potential to incorporate these models into clinical practice as a decision support tool to guide treatment decisions and improve patient outcomes and develop biomarker leads, digital pathology applications, and new predictive models for other cancer types for purposes of drug rescue, drug repurposing and drug combinations.",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "Vennare, Chief Executive Officer and Chairman of <em>Predictive</em> <em>Oncology</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Conference call and webcast details:\n\n<em>Predictive</em> <em>Oncology</em> management will host an investor conference call and webcast on Monday, April 1st, at 8:30am EDT.\n\nTo participate in the call, investors and analysts should dial 1-877-407-3982 (domestic) or 1-201-493-6780 (international) and reference conference ID 13744464.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "Investor Relations Contact:\n\nTim McCarthy, CFA\n\nLifeSci Advisors, LLC\n\[email protected]\n\n<em>PREDICTIVE</em> <em>ONCOLOGY</em> <em>INC</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Predictive</em> <em>Oncology</em> Reports Year End 2023 Financial Results and Provides Business Update",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "5dab08e9-4193-4c0e-b857-7d1e1ff6f1bb",
"title": "Enveric Biosciences : Shareholder Meeting - Form 8-K -March 28, 2024 at 05:27 pm EDT",
"description": "Item 5.08 Shareholder Director Nominations.\n \n \n \n On March 27 2024, Enveric Biosciences, Inc. scheduled the Company's 2024 Annual Meeting of Stockholders for May 28, 2024,...",
"keywords": "Markets",
"snippet": "Item 5.08 Shareholder Director Nominations.\n\nOn March 27 2024, Enveric Biosciences, Inc. (the \"Company\") scheduled the Company's 2024 Annual Meeting of Stockhol...",
"url": "https://www.marketscreener.com/quote/stock/ENVERIC-BIOSCIENCES-INC-38649277/news/Enveric-Biosciences-Shareholder-Meeting-Form-8-K-46315403/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
"language": "en",
"published_at": "2024-03-28T21:27:45.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "ENVB",
"name": "Enveric Biosciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 89.75538,
"sentiment_score": 0,
"highlights": [
{
"highlight": "On March 27 2024, <em>Enveric</em> <em>Biosciences</em>, <em>Inc</em>. (the \"Company\") scheduled the Company's 2024 Annual Meeting of Stockholders (the \"Annual Meeting\") for May 28, 2024, which date is more than 30 days from the first anniversary of the date of the Company's 2023 Annual Meeting of Stockholders that was held on November 2, 2023.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Enveric</em> <em>Biosciences</em> : Shareholder Meeting - Form 8-K -March 28, 2024 at 05:27 pm EDT",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "5a14fa6e-9d0b-4508-b250-c96cba2f1fb7",
"title": "Cepton : Reports Fourth Quarter and Full Year 2023 Results - Form 8-K -March 28, 2024 at 04:09 pm EDT",
"description": "Cepton, Inc. Reports Fourth Quarter and Full Year 2023 Results\n \n \n SAN JOSE, CA, March 28, 2024 - Cepton, Inc. , a Silicon Valley innovator and leader in high performance lidar...",
"keywords": "Markets",
"snippet": "Cepton, Inc. Reports Fourth Quarter and Full Year 2023 Results\n\nSAN JOSE, CA, March 28, 2024 - Cepton, Inc. (\"Cepton\") (Nasdaq: CPTN), a Silicon Valley innovato...",
"url": "https://www.marketscreener.com/quote/stock/CEPTON-INC-133257384/news/Cepton-Reports-Fourth-Quarter-and-Full-Year-2023-Results-Form-8-K-46314689/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-03-28T20:09:53.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "KOTMF",
"name": "Koito Manufacturing Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 14.679573,
"sentiment_score": 0.9042,
"highlights": [
{
"highlight": "Business Highlights\n\nPartnership with Koito\n\n•Received non-binding indication of interest from long-term automotive Tier 1 partner, <em>Koito</em> <em>Manufacturing</em> <em>Co</em>., <em>Ltd</em>. (\"Koito\"), to acquire 100% of our outstanding shares, as disclosed in our 8-K filed on December 21, 2023; the indication of interest is under evaluation.",
"sentiment": 0.9042,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GCAC",
"name": "Growth Capital Acquisition Corp.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 9.757314,
"sentiment_score": 0.23005,
"highlights": [
{
"highlight": "agreements governing such funding, including the consent and other rights granted to Koito as part of Koito's convertible preferred stock investment; (16) Cepton's ability to execute its business plans and strategy; (17) the outcome of any legal proceedings that may be instituted against Cepton, including any related to the business combination with <em>Growth</em>",
"sentiment": 0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Capital</em> <em>Acquisition</em> <em>Corp</em>.; and (18) the other risks and uncertainties indicated from time to time in the reports and documents Cepton files with the Securities and Exchange Commission (the \"SEC\"), including in its Annual Report on Form 10-K.",
"sentiment": -0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GCACW",
"name": "Growth Capital Acquisition Corp.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 9.757314,
"sentiment_score": 0.23005,
"highlights": [
{
"highlight": "agreements governing such funding, including the consent and other rights granted to Koito as part of Koito's convertible preferred stock investment; (16) Cepton's ability to execute its business plans and strategy; (17) the outcome of any legal proceedings that may be instituted against Cepton, including any related to the business combination with <em>Growth</em>",
"sentiment": 0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Capital</em> <em>Acquisition</em> <em>Corp</em>.; and (18) the other risks and uncertainties indicated from time to time in the reports and documents Cepton files with the Securities and Exchange Commission (the \"SEC\"), including in its Annual Report on Form 10-K.",
"sentiment": -0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GCACU",
"name": "Growth Capital Acquisition Corp.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 9.757231,
"sentiment_score": 0.23005,
"highlights": [
{
"highlight": "agreements governing such funding, including the consent and other rights granted to Koito as part of Koito's convertible preferred stock investment; (16) Cepton's ability to execute its business plans and strategy; (17) the outcome of any legal proceedings that may be instituted against Cepton, including any related to the business combination with <em>Growth</em>",
"sentiment": 0.7783,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Capital</em> <em>Acquisition</em> <em>Corp</em>.; and (18) the other risks and uncertainties indicated from time to time in the reports and documents Cepton files with the Securities and Exchange Commission (the \"SEC\"), including in its Annual Report on Form 10-K.",
"sentiment": -0.3182,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "KOTMY",
"name": "Koito Manufacturing Co., Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 14.645668,
"sentiment_score": 0.9042,
"highlights": [
{
"highlight": "Business Highlights\n\nPartnership with Koito\n\n•Received non-binding indication of interest from long-term automotive Tier 1 partner, <em>Koito</em> <em>Manufacturing</em> <em>Co</em>., <em>Ltd</em>. (\"Koito\"), to acquire 100% of our outstanding shares, as disclosed in our 8-K filed on December 21, 2023; the indication of interest is under evaluation.",
"sentiment": 0.9042,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "473cd1c4-70ca-4359-ba94-b93374e24f1a",
"title": "Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)",
"description": "Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an...",
"keywords": "Markets",
"snippet": "Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseas...",
"url": "https://www.marketscreener.com/quote/stock/ADICET-BIO-INC-40332178/news/Adicet-Bio-Reports-Inducement-Grant-under-Nasdaq-Listing-Rule-5635-c-4-46315312/",
"image_url": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
"language": "en",
"published_at": "2024-03-28T21:20:05.000000Z",
"source": "marketscreener.com",
"relevance_score": null,
"entities": [
{
"symbol": "ACET",
"name": "Adicet Bio, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 142.40642,
"sentiment_score": -0.0909,
"highlights": [
{
"highlight": "<em>Adicet</em> <em>Bio</em>, <em>Inc</em>. (<em>Nasdaq</em>: <em>ACET</em>), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024.",
"sentiment": 0.0258,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Adicet</em> <em>Bio</em>, <em>Inc</em>.\n\n<em>Adicet</em> <em>Bio</em>, <em>Inc</em>. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Adicet</em> <em>Bio</em> Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)",
"sentiment": 0.3612,
"highlighted_in": "title"
}
]
}
],
"similar": []
},
{
"uuid": "76f9ec72-d099-47e6-8080-6bb02b070ace",
"title": "Inhibikase Therapeutics, Inc. (IKT) Q4 2023 Earnings Call Transcript",
"description": "Inhibikase Therapeutics, Inc. (NASDAQ:NASDAQ:IKT) Q4 2023 Earnings Call Transcript March 28, 2024 8:00 AM ETCompany ParticipantsAlex Lobo - Stern Investor...",
"keywords": "",
"snippet": "Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Q4 2023 Earnings Call Transcript March 28, 2024 8:00 AM ET\n\nCompany Participants\n\nAlex Lobo - Stern Investor Relation...",
"url": "https://seekingalpha.com/article/4681101-inhibikase-therapeutics-inc-ikt-q4-2023-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-28T21:13:08.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "IKT",
"name": "Inhibikase Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 160.85721,
"sentiment_score": 0.4668,
"highlights": [
{
"highlight": "<em>Inhibikase</em> <em>Therapeutics</em>, <em>Inc</em>. (<em>NASDAQ:IKT</em>) Q4 2023 Earnings Call Transcript March 28, 2024 8:00 AM ET\n\nCompany Participants\n\nAlex Lobo - Stern Investor Relations\n\nMilton Werner - CEO\n\nGarth Lees-Rolfe - CFO\n\nConference Call Participants\n\nOperator\n\nLadies and gentlemen, thank you for standing by.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Greetings, and welcome to <em>Inhibikase</em> <em>Therapeutics</em> Fourth Quarter and Full Year 2023 Financial Results. At this time, all participants will be in listen-only mode. A question-and-answer session will follow the formal presentation. Please note that today's conference is being recorded.",
"sentiment": 0.7964,
"highlighted_in": "main_text"
},
{
"highlight": "Good morning, and welcome to <em>Inhibikase</em> <em>Therapeutics</em> fourth quarter and full year 2023 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer; and Garth Lees-Rolfe, Chief Financial Officer.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Inhibikase</em> <em>Therapeutics</em>, <em>Inc</em>. (IKT) Q4 2023 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "e43d750d-86c2-4a67-9e8c-c672ff6ce39b",
"title": "Apollomics, Inc. (APLM) Q4 2023 Earnings Call Transcript",
"description": "Apollomics, Inc. (NASDAQ:NASDAQ:APLM) Q4 2023 Earnings Conference Call March 28, 2024 8:00 AM ETCompany ParticipantsGuo Liang Yu - Chairman and Chief...",
"keywords": "",
"snippet": "Apollomics, Inc. (NASDAQ:APLM) Q4 2023 Earnings Conference Call March 28, 2024 8:00 AM ET\n\nCompany Participants\n\nGuo Liang Yu - Chairman and Chief Executive Off...",
"url": "https://seekingalpha.com/article/4681085-apollomics-inc-aplm-q4-2023-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-28T19:57:09.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "GLYC",
"name": "GlycoMimetics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 11.930246,
"sentiment_score": 0.811233,
"highlights": [
{
"highlight": "Apollomics licensed apolecylin from <em>glycomimetics</em> including the right to clinical development, production and commercial cells in greater China market. Apollomics is a first in class e selectin inhibitor being used in combination with standard of care chemotherapy in patients with AML.",
"sentiment": 0.8893,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Glycomimetics</em> expects top line results from this trial in the second quarter of 2024.\n\nFinally, in March 2023, we successfully transitioned to a public company by completing our business combination and listing on NASDAQ. With that, I will turn the call over to Sanjeev.\n\nSanjeev Redkar\n\nThank you, Guo Liang.",
"sentiment": 0.7579,
"highlighted_in": "main_text"
},
{
"highlight": "Apollomics, partner in the US, <em>Glycomimetics</em> expects to report top line results from its pivotal phase three study of April Esalan in the relapsed refractory AML in the second quarter of 2024.",
"sentiment": 0.7865,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "af691cb1-4462-4bdd-b016-9444830de728",
"title": "Affimed N.V. (AFMD) Q4 2023 Earnings Call Transcript",
"description": "Affimed N.V. (NASDAQ:NASDAQ:AFMD) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ETCompany ParticipantsAlexander Fudukidis – Head-Investor...",
"keywords": "",
"snippet": "Affimed N.V. (NASDAQ:AFMD) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET\n\nCompany Participants\n\nAlexander Fudukidis – Head-Investor Relations\n\nAn...",
"url": "https://seekingalpha.com/article/4681017-affimed-n-v-afmd-q4-2023-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-28T16:04:42.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "AFMD",
"name": "Affimed N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 125.912384,
"sentiment_score": 0.334933,
"highlights": [
{
"highlight": "<em>Affimed</em> <em>N.V</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:AFMD</em>) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET\n\nCompany Participants\n\nAlexander Fudukidis – Head-Investor Relations\n\nAndreas Harstrick – Chief Medical Officer and Interim Acting Chief Executive Officer\n\nMichael Wolf – Vice President-Finance\n\nConference Call Participants\n\nSrikripa Devarakonda – Truist\n\nDaina Graybosch – Leerink",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "[Operator Instructions]\n\nI would now like to hand the conference over to Alexander Fudukidis, Head of Investor Relations at <em>Affimed</em>. Please go ahead, sir.\n\nAlexander Fudukidis\n\nThank you, Towanda, and thank you all for joining us today for our quarterly update call.",
"sentiment": 0.9001,
"highlighted_in": "main_text"
},
{
"highlight": "In 2023, despite challenges in the broader biotech industry, <em>Affimed</em> not only achieved meaningful milestones that underscore our resilience and commitment to advancing our innovative therapies, but more importantly, we laid the groundwork for significant advances across our three clinical assets, AFM24, Acimtamig and AFM28, in 2024 and beyond.",
"sentiment": 0.8447,
"highlighted_in": "main_text"
},
{
"highlight": "I think 2023 has been a very important and transformative year for <em>Affimed</em>.",
"sentiment": 0.2648,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Affimed</em> <em>N.V</em>. (AFMD) Q4 2023 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
},
{
"symbol": "0HL9.L",
"name": "Affimed N.V.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 122.60199,
"sentiment_score": 0.40192,
"highlights": [
{
"highlight": "<em>Affimed</em> <em>N.V</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "[Operator Instructions]\n\nI would now like to hand the conference over to Alexander Fudukidis, Head of Investor Relations at <em>Affimed</em>. Please go ahead, sir.\n\nAlexander Fudukidis\n\nThank you, Towanda, and thank you all for joining us today for our quarterly update call.",
"sentiment": 0.9001,
"highlighted_in": "main_text"
},
{
"highlight": "In 2023, despite challenges in the broader biotech industry, <em>Affimed</em> not only achieved meaningful milestones that underscore our resilience and commitment to advancing our innovative therapies, but more importantly, we laid the groundwork for significant advances across our three clinical assets, AFM24, Acimtamig and AFM28, in 2024 and beyond.",
"sentiment": 0.8447,
"highlighted_in": "main_text"
},
{
"highlight": "I think 2023 has been a very important and transformative year for <em>Affimed</em>.",
"sentiment": 0.2648,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Affimed</em> <em>N.V</em>. (AFMD) Q4 2023 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "01054e28-363b-437f-93ac-4f60ec34c828",
"title": "Jiayin Group (JFIN) Q4 2023 Earnings Call Transcript",
"description": "Jiayin Group Inc. (NASDAQ:NASDAQ:JFIN) Q4 2023 Earnings Conference Call March 28, 2024 8:00 AM ETCompany ParticipantsDinggui Yan - Chief Executive Officer...",
"keywords": "",
"snippet": "Jiayin Group Inc. (NASDAQ:JFIN) Q4 2023 Earnings Conference Call March 28, 2024 8:00 AM ET\n\nCompany Participants\n\nDinggui Yan - Chief Executive Officer\n\nChunlin...",
"url": "https://seekingalpha.com/article/4681003-jiayin-group-jfin-q4-2023-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-28T15:15:17.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "JFIN",
"name": "Jiayin Group Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 55.096527,
"sentiment_score": 0.426771,
"highlights": [
{
"highlight": "<em>Jiayin</em> <em>Group</em> <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ:JFIN</em>) Q4 2023 Earnings Conference Call March 28, 2024 8:00 AM ET\n\nCompany Participants\n\nDinggui Yan - Chief Executive Officer\n\nChunlin Fan - Chief Financial Officer\n\nYifang Xu - Chief Risk Officer\n\nShawn Zhang - Investor Relations\n\nConference Call Participants\n\nUnknown Analyst - Jinyu Asset Management\n\nYuxuan Chen - HTSC\n\nOperator\n\nGood day",
"sentiment": 0.6808,
"highlighted_in": "main_text"
},
{
"highlight": "ladies and gentlemen, thank you for standing by, and welcome to the <em>Jiayin</em> Group fourth quarter 2023 earnings conference call.",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "Shawn Zhang from Investor Relations of <em>Jiayin</em> Group. Please proceed.\n\nShawn Zhang\n\nThank you Operator. Hello everyone. Thank you all for joining us on today’s conference call to discuss <em>Jiayin</em> Group’s financial results for the fourth quarter and full year of 2023.\n\nWe released our earnings results earlier today.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "In the third quarter, our company officially changed its name to <em>Jiayin</em> Technology, marketing a strategic shift where technology is top priority. This move aligns with the trend of applying AI in various business scenarios.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Going forward, <em>Jiayin</em> will maintain prudent and flexible risk control strategies.\n\nFor new borrower acquisition, we pursued a stable strategy focusing on existing multi-channel borrower acquisition metrics and achieved success in cost control.",
"sentiment": 0.6908,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Jiayin</em> Group (JFIN) Q4 2023 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "d1de23fb-e1c5-4476-b304-542002bd5e78",
"title": "Agile Therapeutics, Inc. (AGRX) Q4 2023 Earnings Call Transcript",
"description": "Agile Therapeutics, Inc. (OTC:AGRX) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ETCompany ParticipantsMatt Riley - Head of Investor Relations...",
"keywords": "",
"snippet": "Agile Therapeutics, Inc. (OTC:AGRX) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET\n\nCompany Participants\n\nMatt Riley - Head of Investor Relations an...",
"url": "https://seekingalpha.com/article/4680991-agile-therapeutics-inc-agrx-q4-2023-earnings-call-transcript",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-28T14:46:06.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "SKLTF",
"name": "SEEK Limited",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 9.649002,
"sentiment_score": 0.8787,
"highlights": [
{
"highlight": "We continue to believe in our business model and its emphasis on partnerships to maximize Twirla’s growth potential. 2024 is a pivotal year for both the company and the brand, and we will explore any and all strategic opportunities, both internally and externally, as we <em>seek</em> to maximize Twirla growth and increase shareholder value.",
"sentiment": 0.8885,
"highlighted_in": "main_text"
},
{
"highlight": "We will continue to explore any and all opportunities as we <em>seek</em> to grow Twirla and shareholder value.\n\nThis will conclude today’s call, and we can encourage everyone to stay tuned for additional updates related to Agile Therapeutics and Twirla. Thank you again for joining us for this call and following us along.",
"sentiment": 0.8689,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "AGRX",
"name": "Agile Therapeutics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 139.70627,
"sentiment_score": 0.452,
"highlights": [
{
"highlight": "<em>Agile</em> <em>Therapeutics</em>, <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(OTC:AGRX) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET\n\nCompany Participants\n\nMatt Riley - Head of Investor Relations and Corporate Communications\n\nAl Altomari - Chairman and Chief Executive Officer\n\nOperator\n\nGood morning, and welcome to the <em>Agile</em> <em>Therapeutics</em> Fourth Quarter and Full Year 2023 Financial Results Conference Call.",
"sentiment": 0.7096,
"highlighted_in": "main_text"
},
{
"highlight": "Joining me on today call is Al Altomari, <em>Agile</em> <em>Therapeutics</em>’ Chair and Chief Executive Officer.\n\nAl Altomari\n\nThank you very much, Matt, and thank you all for joining us today on our call. 2023 was a year for <em>Agile</em> <em>Therapeutics</em> that we believe demonstrated our ability to continue to grow Twirla.",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "This will conclude today’s call, and we can encourage everyone to stay tuned for additional updates related to <em>Agile</em> <em>Therapeutics</em> and Twirla. Thank you again for joining us for this call and following us along.\n\nQuestion-and-Answer Session\n\nQ -\n\nOperator\n\nThis concludes today’s conference call. Thank for your participation. You may now disconnect.",
"sentiment": 0.8074,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Agile</em> <em>Therapeutics</em>, <em>Inc</em>. (AGRX) Q4 2023 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "4f32bb24-0f20-49ff-a1eb-9d6bbab44180",
"title": "GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript",
"description": "Operator: Good morning, and thank you for joining the GlycoMimetics Q4 and Full Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.",
"keywords": "",
"snippet": "GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript March 27, 2024\n\nGlycoMimetics, Inc. isn’t one of the 30 most popular stocks among hedge fun...",
"url": "https://www.insidermonkey.com/blog/glycomimetics-inc-nasdaqglyc-q4-2023-earnings-call-transcript-1281823/",
"image_url": "https://d2gr5kl7dt2z3t.cloudfront.net/blog/wp-content/uploads/2023/11/14170045/GLYC-insidermonkey-1699999244037.jpg",
"language": "en",
"published_at": "2024-03-28T14:12:43.000000Z",
"source": "insidermonkey.com",
"relevance_score": null,
"entities": [
{
"symbol": "GLYC",
"name": "GlycoMimetics, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 158.3142,
"sentiment_score": 0.340273,
"highlights": [
{
"highlight": "<em>GlycoMimetics</em>, <em>Inc</em>. (<em>NASDAQ:GLYC</em>) Q4 2023 Earnings Call Transcript March 27, 2024\n\n<em>GlycoMimetics</em>, <em>Inc</em>. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).\n\nOperator: Good morning, and thank you for joining the <em>GlycoMimetics</em> Q4 and Full Year 2023 Earnings Call.",
"sentiment": 0.8158,
"highlighted_in": "main_text"
},
{
"highlight": "[Operator Instructions] I would now like to turn the call over to Christian Dinneen-Long, Company Counsel at <em>GlycoMimetics</em>. Please go ahead.\n\nChristian Dinneen-Long: Good morning. Today, we will review our business updates and financial results for the quarter and year ended December 31, 2023.",
"sentiment": 0.7717,
"highlighted_in": "main_text"
},
{
"highlight": "On the call today from <em>GlycoMimetics</em> are Harout Semerjian, Chief Executive Officer; Brian Hahn, Chief Financial Officer; Dr. Edwin Rock, Chief Medical Officer; and Bruce Johnson, Chief Commercial Officer. Today’s call will include forward-looking statements based on our current expectations.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>GlycoMimetics</em> undertakes no obligation to update or revise any forward-looking statement. For information concerning the risk factors that could affect the company, please refer to our filings with the SEC, which are available from the SEC or through the <em>GlycoMimetics</em> website.\n\nI’ll now turn the call over to Harout.",
"sentiment": -0.25,
"highlighted_in": "main_text"
},
{
"highlight": "Building on the advances we made in 2023, I believe 2024 will be a transformational year for <em>GlycoMimetics</em>. In the second quarter of this year, we expect to report top line results from our Phase III trial of our lead drug candidate, uproleselan.",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "I want to thank the entire <em>GlycoMimetics</em> team, our shareholders, collaborators, investigators, trial sites and patients for their trust, commitment and resilience during this multiyear Phase III trial, which has now reached clinical maturity.",
"sentiment": 0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "As we look ahead to 2024 and beyond, we believe <em>GlycoMimetics</em> is well-positioned to deliver innovative glycobiology-based medicines to patients in need of new treatment options, beginning with uproleselan.",
"sentiment": 0.4404,
"highlighted_in": "main_text"
},
{
"highlight": "Through this relationship, <em>GlycoMimetics</em> will obtain feedback from experts and people living with sickle cell disease on our GMI-1687 clinical development plan.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "As of December 31, 2023, <em>GlycoMimetics</em> had cash and cash equivalents of $41.8 million as compared to $47.9 million as of December 31, 2022. This increase was due to the company’s ability to raise additional cash early in the year.",
"sentiment": 0.5574,
"highlighted_in": "main_text"
},
{
"highlight": "Q&A Session\n\nFollow <em>Glycomimetics</em> <em>Inc</em> (<em>NASDAQ:GLYC</em>) Follow <em>Glycomimetics</em> <em>Inc</em> (<em>NASDAQ:GLYC</em>) or Subscribe with Google We may use your email to send marketing emails about our services. Click here to read our privacy policy.\n\nOperator: Thank you. [Operator Instructions] Our first question comes from Tara Bancroft with TD Cowen. Your line is open.",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>GlycoMimetics</em>, <em>Inc</em>. (<em>NASDAQ:GLYC</em>) Q4 2023 Earnings Call Transcript",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "96bb53d4-9e47-4176-b9be-72bd91e2b165",
"title": "Immunome GAAP EPS of -$5.38 (NASDAQ:IMNM)",
"description": "Immunome reports FY 2023 financial results with GAAP EPS of -$5.38.",
"keywords": "",
"snippet": "To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.\n\nIf you have an ad-blocker enabled you may be blocked from ...",
"url": "https://seekingalpha.com/news/4085222-immunome-gaap-eps-of-5_38",
"image_url": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
"language": "en",
"published_at": "2024-03-28T21:07:10.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "IMNM",
"name": "Immunome, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 107.293564,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Immunome</em> GAAP EPS of -$5.38 (<em>NASDAQ:IMNM</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "NASDAQ",
"total_documents": 1613,
"sentiment_avg": 0.29044090647948906
}
]
}
Other details
Country
- us
- 5,275